BlossomHill 制药

BlossomHill Therapeutics Inc earns a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 30% discount to our quantitative fair value estimate of $23.80 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's balance sheet bolsters our fair value estimate. Low leverage mitigates financial risk, potentially boosting a firm's value. For example, the firm's current ratio of 5.4 falls in the top 20% globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are cheap.

On a different note, the company's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to market value ratio of 1.3, a core component of valuation, sits in the top 40% globally. The market value of equity is low relative to the business' enterprise value, suggesting the company could be buried in debt if anything goes wrong. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none.